[go: up one dir, main page]

JO3121B1 - مشتقات 1 - ((5-هيتيرورلثيازول-2-يل) أمينوكاربونيل) بيروليدين-2-كربوكساميد كمثبات الفوسفاتديلينوسيتول 3-كيناس (pi3k) مفيدة في علاج الأمراض التصاعدية - Google Patents

مشتقات 1 - ((5-هيتيرورلثيازول-2-يل) أمينوكاربونيل) بيروليدين-2-كربوكساميد كمثبات الفوسفاتديلينوسيتول 3-كيناس (pi3k) مفيدة في علاج الأمراض التصاعدية

Info

Publication number
JO3121B1
JO3121B1 JOP/2009/0334A JOP20090334A JO3121B1 JO 3121 B1 JO3121 B1 JO 3121B1 JO P20090334 A JOP20090334 A JO P20090334A JO 3121 B1 JO3121 B1 JO 3121B1
Authority
JO
Jordan
Prior art keywords
kinase
treatment
heteroarylthiazol
pi3k
phosphatidylinositol
Prior art date
Application number
JOP/2009/0334A
Other languages
English (en)
Inventor
Imbach Patricia
Furet Pascal
Caravatti Giorgio
Alec Fairhurst Robin
Guagnano Vito
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40350060&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JO3121(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Application granted granted Critical
Publication of JO3121B1 publication Critical patent/JO3121B1/ar

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)
  • Neurosurgery (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Biomedical Technology (AREA)
  • Oncology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Transplantation (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Communicable Diseases (AREA)
  • Hospice & Palliative Care (AREA)
  • Endocrinology (AREA)
  • Virology (AREA)

Abstract

يتعلق الإختراع الحالي بمركب الصيغة (I) (I) أو ملح من ذلك، الذى به المستبدلات كما عرف في الوصف، إلى التراكيب وإستعمال المركبات في معالجة أمراض المحسنة ameloriated بمنع فوسفاتيديل لينوسيتول 3-كينيز.
JOP/2009/0334A 2008-09-10 2009-09-09 مشتقات 1 - ((5-هيتيرورلثيازول-2-يل) أمينوكاربونيل) بيروليدين-2-كربوكساميد كمثبات الفوسفاتديلينوسيتول 3-كيناس (pi3k) مفيدة في علاج الأمراض التصاعدية JO3121B1 (ar)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP08164104 2008-09-10
US9667408P 2008-09-12 2008-09-12

Publications (1)

Publication Number Publication Date
JO3121B1 true JO3121B1 (ar) 2017-09-20

Family

ID=40350060

Family Applications (1)

Application Number Title Priority Date Filing Date
JOP/2009/0334A JO3121B1 (ar) 2008-09-10 2009-09-09 مشتقات 1 - ((5-هيتيرورلثيازول-2-يل) أمينوكاربونيل) بيروليدين-2-كربوكساميد كمثبات الفوسفاتديلينوسيتول 3-كيناس (pi3k) مفيدة في علاج الأمراض التصاعدية

Country Status (50)

Country Link
US (4) US8227462B2 (ar)
EP (1) EP2331537B1 (ar)
JP (1) JP5486601B2 (ar)
KR (1) KR101290844B1 (ar)
CN (1) CN102149711B (ar)
AR (2) AR073369A1 (ar)
AU (1) AU2009290904B2 (ar)
BR (1) BRPI0918750B8 (ar)
CA (1) CA2734819C (ar)
CL (1) CL2011000504A1 (ar)
CO (1) CO6351738A2 (ar)
CR (1) CR20110059A (ar)
CU (1) CU24000B1 (ar)
CY (2) CY1117078T1 (ar)
DK (1) DK2331537T3 (ar)
DO (1) DOP2011000070A (ar)
EA (1) EA018863B1 (ar)
EC (1) ECSP11010880A (ar)
ES (1) ES2560673T3 (ar)
FI (1) FIC20200046I1 (ar)
GE (1) GEP20135991B (ar)
HN (1) HN2011000699A (ar)
HR (1) HRP20160014T1 (ar)
HU (2) HUE025884T2 (ar)
IL (1) IL210976A (ar)
JO (1) JO3121B1 (ar)
LT (1) LTC2331537I2 (ar)
LU (1) LUC00186I2 (ar)
MA (1) MA32604B1 (ar)
ME (1) ME01284B (ar)
MX (1) MX2011002597A (ar)
MY (1) MY151556A (ar)
NI (1) NI201100049A (ar)
NL (1) NL301071I2 (ar)
NO (1) NO2020037I1 (ar)
NZ (1) NZ590754A (ar)
PA (1) PA8841901A1 (ar)
PE (1) PE20110796A1 (ar)
PL (1) PL2331537T3 (ar)
PT (1) PT2331537E (ar)
RS (1) RS54476B1 (ar)
SI (1) SI2331537T1 (ar)
SM (1) SMP201100019B (ar)
SV (1) SV2011003853A (ar)
TN (1) TN2011000053A1 (ar)
TW (1) TWI453206B (ar)
UA (1) UA104147C2 (ar)
UY (1) UY32096A (ar)
WO (1) WO2010029082A1 (ar)
ZA (1) ZA201100699B (ar)

Families Citing this family (111)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR044519A1 (es) * 2003-05-02 2005-09-14 Novartis Ag Derivados de piridin-tiazol amina y de pirimidin-tiazol amina
RU2508110C2 (ru) 2008-07-11 2014-02-27 Новартис Аг КОМБИНАЦИЯ (А) ИНГИБИТОРА ФОСФОИНОЗИТ-3-КИНАЗЫ И (Б) МОДУЛЯТОРА ПУТИ Ras/Raf/Mek
UA104147C2 (uk) * 2008-09-10 2014-01-10 Новартис Аг Похідна піролідиндикарбонової кислоти та її застосування у лікуванні проліферативних захворювань
US8293753B2 (en) * 2009-07-02 2012-10-23 Novartis Ag Substituted 2-carboxamide cycloamino ureas
AR082418A1 (es) 2010-08-02 2012-12-05 Novartis Ag Formas cristalinas de 1-(4-metil-5-[2-(2,2,2-trifluoro-1,1-dimetil-etil)-piridin-4-il]-tiazol-2-il)-amida de 2-amida del acido (s)-pirrolidin-1,2-dicarboxilico
KR101854484B1 (ko) * 2010-11-08 2018-05-03 노파르티스 아게 Ｅｇｆｒ 의존성 질환 또는 ｅｇｆｒ 족 구성원을 표적으로 하는 작용제에 대한 내성을 획득한 질환의 치료에서의 2-카르복사미드 시클로아미노 우레아 유도체의 용도
AU2015203865B2 (en) * 2010-11-08 2016-11-03 Novartis Ag Use of 2-carboxamide cycloamino urea derivatives in the treatment of EGFR dependent diseases or diseases that have acquired resistance to agents that target EGFR family members
UA112539C2 (uk) 2011-03-03 2016-09-26 Новартіс Аг Спосіб одержання похідних 2-карбоксамідциклоаміносечовини
PH12013502077A1 (en) * 2011-04-25 2013-12-16 Novartis Ag Combination of a phosphatidylinositol-3-kinase (pi3k) inhibitor and a mtor inhibitor
RU2014101626A (ru) * 2011-06-21 2015-07-27 Новартис Аг Полиморфы 2-амид 1-({4-метил-5-[2-(2, 2, 2-трифтор-1, 1-диметил-этил)-пиридин-4-ил]тиазол-2-ил}амида) (s)-пирролидин-1, 2-дикарбоновой кислоты
PE20141381A1 (es) 2011-07-01 2014-10-21 Novartis Ag Terapia de combinacion que comprende un inhibidor de cdk4/6 y un inhibidor de pi3k para el uso en el tratamiento de cancer
WO2013066483A1 (en) 2011-08-31 2013-05-10 Novartis Ag Synergistic combinations of pi3k- and mek-inhibitors
WO2013049581A1 (en) * 2011-09-30 2013-04-04 Beth Israel Deaconess Medical Center Inc. Compositions and methods for the treatment of proliferative diseases
JP6180420B2 (ja) * 2011-10-14 2017-08-16 ノバルティス アーゲー 増殖性疾患の治療のためのｈｓｐ９０阻害剤と組み合わせた２−カルボキサミドシクロアミノウレア誘導体
CN103889422A (zh) * 2011-10-28 2014-06-25 诺华股份有限公司 治疗胃肠道间质瘤的方法
AU2012331125A1 (en) 2011-11-02 2014-05-22 Novartis Ag 2-carboxamide cycloamino urea derivatives for use in treating VEGF - dependent diseases
RU2627701C2 (ru) * 2012-02-22 2017-08-10 Сэнфорд-Бёрнхэм Медикал Рисёрч Инститьют Сульфонамидные соединения и их применение в качестве ингибиторов tnap
ES2845560T3 (es) 2012-03-29 2021-07-27 Novartis Ag Diagnóstico farmacéutico
CA2865993A1 (en) 2012-03-30 2013-10-03 Novartis Ag Compounds for use in the treatment of neuroblastoma, ewing's sarcoma or rhabdomyosarcoma
KR20160027217A (ko) 2012-05-23 2016-03-09 에프. 호프만-라 로슈 아게 내배엽 및 간세포를 수득하고 사용하는 조성물 및 방법
US8980259B2 (en) * 2012-07-20 2015-03-17 Novartis Ag Combination therapy
US9474754B2 (en) * 2012-08-07 2016-10-25 Novartis Ag Pharmaceutical combinations comprising a B-RAF inhibitor, and EGFR inhibitor and optionally a PI3K-α inhibitor
ES2901712T3 (es) * 2012-08-16 2022-03-23 Novartis Ag Combinación de un inhibidor de pi3k y un inhibidor de c-met.
JP6212563B2 (ja) * 2012-09-20 2017-10-11 ノバルティス アーゲー ホスファチジルイノシトール３−キナーゼ阻害剤およびアロマターゼ阻害剤を含む組合せ医薬
SG11201503628YA (en) * 2012-11-16 2015-06-29 Merck Patent Gmbh 3-aminocyclopentane carboxamide derivatives
EP3251673A1 (en) 2012-12-13 2017-12-06 IP Gesellschaft für Management mbH Combination therapy comprising a cdk4/6 inhibitor and a pi3k inhibitor for use in the treatment of cancer
BR112015017331B1 (pt) 2013-01-23 2022-01-11 Astrazeneca Ab Compostos de formula i, forma cristalina, uso dos compostos, combinação e composição
US20160143910A1 (en) 2013-03-15 2016-05-26 Constellation Pharmaceuticals, Inc. Methods of treating cancer and preventing cancer drug resistance
PE20151785A1 (es) * 2013-03-21 2015-12-20 Novartis Ag Terapia de combinacion
US20160030440A1 (en) * 2013-04-05 2016-02-04 Sanofi Anti-tumoral composition comprising a pi3kbeta-selective inhibitor and a pi3kalpha-selective inhibitor
EP3003377A1 (en) 2013-05-31 2016-04-13 Novartis AG Combination therapy containing a pi3k-alpha inhibitor and fgfr kinase inhibitor for treating cancer
CA2912346A1 (en) 2013-06-11 2014-12-18 Novartis Ag Pharmaceutical combinations of a pi3k inhibitor and a microtubule destabilizing agent
WO2014203152A1 (en) 2013-06-18 2014-12-24 Novartis Ag Pharmaceutical combinations
BR112016002311A2 (pt) 2013-08-08 2017-08-01 Novartis Ag combinações de inibidor de cinase de pim
DK3033086T3 (da) 2013-08-14 2022-01-03 Novartis Ag Kombinationsterapi til behandling af cancer
US10570204B2 (en) 2013-09-26 2020-02-25 The Medical College Of Wisconsin, Inc. Methods for treating hematologic cancers
HUE057092T2 (hu) * 2013-12-06 2022-04-28 Novartis Ag Alfa-izoformára szelektív foszfatidilinozitol-3-kináz-inhibitor adagolási rendje
RU2020121929A (ru) * 2014-01-15 2020-07-13 Новартис Аг Фармацевтические комбинации
JOP20200094A1 (ar) 2014-01-24 2017-06-16 Dana Farber Cancer Inst Inc جزيئات جسم مضاد لـ pd-1 واستخداماتها
JOP20200096A1 (ar) 2014-01-31 2017-06-16 Children’S Medical Center Corp جزيئات جسم مضاد لـ tim-3 واستخداماتها
US20170165246A1 (en) 2014-02-11 2017-06-15 Novartis Ag Pharmaceutical combinations comprising a pi3k inhibitor for the treatment of cancer
PH12016501545B1 (en) 2014-03-14 2023-12-06 Immutep Sas Antibody molecules to lag-3 and uses thereof
WO2016040880A1 (en) 2014-09-13 2016-03-17 Novartis Ag Combination therapies of alk inhibitors
WO2016051374A1 (en) 2014-10-03 2016-04-07 Novartis Ag Pharmaceutical compositions comprising alpelisib
EP3662903A3 (en) 2014-10-03 2020-10-14 Novartis AG Combination therapies
MA41044A (fr) 2014-10-08 2017-08-15 Novartis Ag Compositions et procédés d'utilisation pour une réponse immunitaire accrue et traitement contre le cancer
KR102513870B1 (ko) 2014-10-14 2023-03-23 노파르티스 아게 Pd-l1에 대한 항체 분자 및 그의 용도
CN104844589B (zh) * 2014-12-26 2018-04-20 中国科学院合肥物质科学研究院 一种pi3k激酶抑制剂
EP3268035A4 (en) 2015-03-10 2018-10-31 Aduro Biotech, Inc. Compositions and methods for activating "stimulator of interferon gene" -dependent signalling
JP2018509448A (ja) * 2015-03-25 2018-04-05 ノバルティス アーゲー 組合せ医薬
WO2017001362A1 (en) 2015-06-29 2017-01-05 F. Hoffmann-La Roche Ag Methods of treatment with taselisib
PE20211775A1 (es) 2015-07-02 2021-09-08 Hoffmann La Roche Compuestos de benzoxacepina oxazolidinona y metodos de uso
EP3964528A1 (en) 2015-07-29 2022-03-09 Novartis AG Combination therapies comprising antibody molecules to lag-3
CN108025051B (zh) 2015-07-29 2021-12-24 诺华股份有限公司 包含抗pd-1抗体分子的联合疗法
EP3316902A1 (en) 2015-07-29 2018-05-09 Novartis AG Combination therapies comprising antibody molecules to tim-3
EP3341023A1 (en) 2015-08-28 2018-07-04 Novartis AG Combination therapy using pi3k inhbitor and mdm2 inhibitor
WO2017037574A1 (en) 2015-08-28 2017-03-09 Novartis Ag Combinations of the cdk4/6 inhibitor lee011 and the mek1/2 inhibitor trametinib, optionally further comprising the pi3k inhibitor byl719 to treat cancer
CN108348520A (zh) 2015-08-28 2018-07-31 诺华股份有限公司 Mdm2抑制剂和其组合
WO2017037575A1 (en) 2015-08-28 2017-03-09 Novartis Ag A pharmaceutical combination comprising the pi3k inhibitor alpelisib and the cdk4/6 inhibitor ribociclib, and the use thereof in the treatment/prevention of cancer
US20180256557A1 (en) 2015-08-28 2018-09-13 Giordano Caponigro Pharmaceutical combination comprising (a) the alpha-isoform specific pi3k inhibitor alpelisib (byl719) and (b) an akt inhibitor, preferably mk-2206, afuresertib or uprosertib, and the use thereof in the treatment/prevention of cancer
WO2017037587A1 (en) 2015-08-28 2017-03-09 Novartis Ag Combination of ribociclib and dabrafenib for treating or preventing cancer
TW201726140A (zh) 2015-09-17 2017-08-01 瑞典商阿斯特捷利康公司 治療癌症之新型生物標記及方法
CN105294546B (zh) * 2015-10-29 2017-12-08 天津市斯芬克司药物研发有限公司 一种吡啶化合物及其制备方法
AU2016347881A1 (en) 2015-11-02 2018-05-10 Novartis Ag Dosage regimen for a phosphatidylinositol 3-kinase inhibitor
EP4046655A1 (en) 2015-11-03 2022-08-24 Janssen Biotech, Inc. Antibodies specifically binding pd-1 and their uses
US20180353515A1 (en) 2015-12-03 2018-12-13 Novartis Ag Treatment of cancer with a pi3k inhibitor in a patient presselected for having a pik3ca mutation in the ctdna
JP2019503349A (ja) 2015-12-17 2019-02-07 ノバルティス アーゲー Ｐｄ−１に対する抗体分子およびその使用
EP3507367A4 (en) 2016-07-05 2020-03-25 Aduro BioTech, Inc. CYCLIC DINUCLEOTID COMPOUNDS WITH INCLUDED NUCLEIC ACIDS AND USES THEREOF
WO2018060833A1 (en) 2016-09-27 2018-04-05 Novartis Ag Dosage regimen for alpha-isoform selective phosphatidylinositol 3-kinase inhibitor alpelisib
WO2018092064A1 (en) 2016-11-18 2018-05-24 Novartis Ag Combinations of mdm2 inhibitors and bcl-xl inhibitors
CN106674200B (zh) * 2016-12-21 2019-04-12 西安交通大学 一种含有l-脯氨酰胺片段的化合物及其制备方法和应用
UY37695A (es) 2017-04-28 2018-11-30 Novartis Ag Compuesto dinucleótido cíclico bis 2’-5’-rr-(3’f-a)(3’f-a) y usos del mismo
EP3642240A1 (en) 2017-06-22 2020-04-29 Novartis AG Antibody molecules to cd73 and uses thereof
MA49457A (fr) 2017-06-22 2020-04-29 Novartis Ag Molécules d'anticorps se liant à cd73 et leurs utilisations
EP3694511A1 (en) 2017-10-13 2020-08-19 INSERM (Institut National de la Santé et de la Recherche Médicale) Combination treatment of pancreatic cancer
EP3713963A1 (en) 2017-11-23 2020-09-30 INSERM (Institut National de la Santé et de la Recherche Médicale) A new marker for predicting the sensitivity to pi3k inhibitors
JP2021504384A (ja) 2017-12-01 2021-02-15 ノバルティス アーゲー Ｌｓｚ１０２及びアルペリシブを含む医薬品の組合せ
KR102716244B1 (ko) * 2017-12-08 2024-10-14 버텍스 파마슈티칼스 인코포레이티드 낭포성 섬유증 막횡단 전도 조절자의 조정제의 제조 방법
US12398209B2 (en) 2018-01-22 2025-08-26 Janssen Biotech, Inc. Methods of treating cancers with antagonistic anti-PD-1 antibodies
CN112074505B (zh) 2018-03-08 2024-04-05 因赛特公司 作为PI3K-γ抑制剂的氨基吡嗪二醇化合物
AU2019276514B2 (en) 2018-05-30 2023-12-14 Jiangsu Hansoh Pharmaceutical Group Co., Ltd. Inhibitor containing tricyclic derivative, preparation method therefor, and application thereof
TWI869346B (zh) 2018-05-30 2025-01-11 瑞士商諾華公司 Ｅｎｔｐｄ２抗體、組合療法、及使用該等抗體和組合療法之方法
US20210214459A1 (en) 2018-05-31 2021-07-15 Novartis Ag Antibody molecules to cd73 and uses thereof
WO2020010003A1 (en) 2018-07-02 2020-01-09 Incyte Corporation AMINOPYRAZINE DERIVATIVES AS PI3K-γ INHIBITORS
WO2020053125A1 (en) * 2018-09-10 2020-03-19 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for the treatment of neurofibromatosis
EP3860597A4 (en) 2018-10-05 2022-08-17 Sloan-Kettering Institute for Cancer Research PI3K INHIBITORS AND USES THEREOF
EP3903828A4 (en) 2018-12-21 2022-10-05 Daiichi Sankyo Company, Limited ANTIBODY-DRUG CONJUGATE AND KINAS INHIBITOR COMBINATION
KR20220008313A (ko) 2019-05-13 2022-01-20 뤄신 헬스케어 사이언스 앤드 테크놀로지 디벨롭먼트 (베이징) 리미티드 퀴나졸리논계 화합물의 결정형 및 이의 제조방법
CN111995541B (zh) * 2019-05-27 2025-05-06 君实润佳(上海)医药科技有限公司 含有稳定重同位素的酰胺官能团的化合物及其应用
WO2021001431A1 (en) 2019-07-02 2021-01-07 INSERM (Institut National de la Santé et de la Recherche Médicale) Use of pi3ka-selective inhibitors for treating metastatic disease in patients suffering from pancreatic cancer
WO2021001426A1 (en) 2019-07-02 2021-01-07 INSERM (Institut National de la Santé et de la Recherche Médicale) Use of ultrafast elasticity imaging for detecting pancreatic cancers
US20220354863A1 (en) 2019-07-02 2022-11-10 Inserm (Institut National De La Santè Et De La Recherch Médicale) Methods for the prophylactic treatment of cancer in patients suffering from pancreatitis
WO2021007146A1 (en) 2019-07-07 2021-01-14 Olema Pharmaceuticals, Inc. Regimens of estrogen receptor antagonists
IL290789B2 (en) 2019-08-26 2025-09-01 Arvinas Operations Inc Methods for treating breast cancer with a history of tetrahydronaphthalene as estrogen receptor-disrupting agents
EP4031578A1 (en) 2019-09-18 2022-07-27 Novartis AG Entpd2 antibodies, combination therapies, and methods of using the antibodies and combination therapies
CA3159094A1 (en) 2019-11-25 2021-06-03 Shanghai Hansoh Biomedical Co., Ltd. Three fused ring derivative-containing salt or crystal form and pharmaceutical composition thereof
CN113045564B (zh) * 2019-12-27 2024-09-20 上海天慈国际药业有限公司 一种阿培利司的制备方法
US12365675B2 (en) 2020-03-25 2025-07-22 Risen (Suzhou) Pharma Tech Co., Ltd. Stable heavy isotopes in amide functional groups and uses thereof
WO2022016420A1 (zh) * 2020-07-22 2022-01-27 罗欣药业(上海)有限公司 一种喹唑啉酮类化合物的晶型、其制备方法及应用
WO2022234408A1 (en) 2021-05-03 2022-11-10 Novartis Ag Alpelisib formulation
CN115611883B (zh) * 2021-07-13 2025-03-28 生物岛实验室 一种双环结构的PI3Kα抑制剂及其制备方法和用途
EP4412716A4 (en) 2021-10-05 2025-08-13 Mirati Therapeutics Inc COMBINATIONS OF KRAS G12D INHIBITORS AND PI3KA INHIBITORS AND RELATED METHODS OF TREATMENT
WO2023083330A1 (zh) * 2021-11-12 2023-05-19 百极优棠(广东)医药科技有限公司 Drak2抑制剂及其制备方法和应用
EP4230196A1 (en) 2022-02-21 2023-08-23 Som Innovation Biotech, S.A. Compounds for use in the treatment of dystrophinopathies
EP4608509A1 (en) 2022-10-28 2025-09-03 Institut National de la Santé et de la Recherche Médicale New inhibitors of phosphatidylinositol 3-kinase
EP4615431A1 (en) 2022-11-11 2025-09-17 Astrazeneca AB Combination therapies for the treatment of cancer
CN116239591B (zh) * 2023-02-14 2025-09-23 嘉兴大学 一种(4r)-磺酰氨基-l-脯氨酰胺类化合物、制备方法、应用及其药物组合
TW202440096A (zh) 2023-03-24 2024-10-16 美商亞文納營運公司 雌激素受體降解劑之給藥方案
CN116987072A (zh) * 2023-07-27 2023-11-03 武汉呈瑞生物医药科技有限公司 化合物及其应用
WO2025181153A1 (en) 2024-03-01 2025-09-04 F. Hoffmann-La Roche Ag Use of atr inhibitors in combination with pi3k alpha inhibitors
EP4643858A1 (en) * 2024-04-29 2025-11-05 Institut National de la Santé et de la Recherche Médicale Methods and pharmaceutical composition for the treatment of uterine disease

Family Cites Families (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4649146A (en) 1983-01-31 1987-03-10 Fujisawa Pharmaceutical Co., Ltd. Thiazole derivatives and pharmaceutical composition comprising the same
DE3703435A1 (de) 1987-02-05 1988-08-18 Thomae Gmbh Dr K Neue thiazole, diese verbindungen enthaltende arzneimittel und verfahren zu ihrer herstellung
EP0373226B1 (en) 1988-04-15 1994-06-15 Taiho Pharmaceutical Company, Limited Carbamoyl-2-pyrrolidinone compounds
US5028726A (en) * 1990-02-07 1991-07-02 The University Of Vermont And State Agricultural College Platinum amine sulfoxide complexes
US5780653A (en) * 1995-06-07 1998-07-14 Vivorx Pharmaceuticals, Inc. Nitrophenyl, 10-deacetylated substituted taxol derivatives as dual functional cytotoxic/radiosensitizers
JP2001505585A (ja) 1996-12-16 2001-04-24 藤沢薬品工業株式会社 新規アミド化合物およびそれらの一酸化窒素シンターゼ阻害剤としての用途
US6187797B1 (en) 1996-12-23 2001-02-13 Dupont Pharmaceuticals Company Phenyl-isoxazoles as factor XA Inhibitors
US6387638B1 (en) * 1997-02-10 2002-05-14 Genentech, Inc. Heregulin variants
WO1999021555A2 (en) 1997-10-27 1999-05-06 Takeda Chemical Industries, Ltd. Adenosine a3 receptor antagonists
JP2002518380A (ja) 1998-06-18 2002-06-25 ブリストル−マイヤーズ スクイブ カンパニー サイクリン依存キナーゼの炭素置換アミノチアゾール抑制剤
DE60023926T2 (de) 1999-09-10 2006-07-20 Merck & Co., Inc. Tyrosin kinase inhibitoren
GB0000313D0 (en) * 2000-01-10 2000-03-01 Astrazeneca Uk Ltd Formulation
CN100355751C (zh) 2000-03-29 2007-12-19 西克拉塞尔有限公司 2－取代的4－杂芳基－嘧啶、其组合物及其用途
JP3712393B2 (ja) 2000-10-20 2005-11-02 エーザイ株式会社 含窒素芳香環誘導体
ES2254611T3 (es) 2001-05-11 2006-06-16 Pfizer Products Inc. Derivados de tiazol.
HUP0401748A3 (en) 2001-08-13 2011-03-28 Janssen Pharmaceutica Nv 2-amino-4,5-trisubstituted thiazolyl derivatives, process for their preparation and pharmaceutical compositions containing them
WO2003015778A1 (en) 2001-08-17 2003-02-27 Merck & Co., Inc. Tyrosine kinase inhibitors
MXPA04002914A (es) 2001-09-28 2005-06-20 Cyclacel Ltd N- (4- (4-metiltiazol-5-il)pirimidin-2-il) -n-fenilaminas como compuestos antiproliferativos.
PE20030968A1 (es) * 2002-02-28 2004-01-12 Novartis Ag Derivados de 5-feniltiazol como inhibidores de cinasas
AR043057A1 (es) 2002-10-30 2005-07-13 Vertex Pharma Compuestos derivados de piridintiazoles como inhibidores de la quinasa rock y otras proteinas quinasa
EP1567487A4 (en) 2002-11-15 2005-11-16 Bristol Myers Squibb Co OPEN-CHAINED, PROLYL-FROSTED MODULATORS OF ANDROGEN RECEPTOR FUNCTION
AU2004204778B2 (en) * 2003-01-10 2008-05-22 Threshold Pharmaceuticals, Inc. Treatment of cancer with 2-deoxyglucose
GB0305152D0 (en) 2003-03-06 2003-04-09 Novartis Ag Organic compounds
AR044519A1 (es) * 2003-05-02 2005-09-14 Novartis Ag Derivados de piridin-tiazol amina y de pirimidin-tiazol amina
GB0320197D0 (en) * 2003-08-28 2003-10-01 Novartis Ag Organic compounds
CA2537841A1 (en) 2003-09-06 2005-03-24 Vertex Pharmaceuticals Incorporated Modulators of atp-binding cassette transporters
EP1709019B1 (en) 2004-01-12 2007-08-08 Applied Research Systems ARS Holding N.V. Thiazole derivatives and use thereof
EP1768982A2 (en) * 2004-06-29 2007-04-04 Amgen Inc. Pyrolo [2,3-d] pyrimidines that modulate ack1 and lck activity
SE0402735D0 (sv) * 2004-11-09 2004-11-09 Astrazeneca Ab Novel compounds
PT2301531T (pt) * 2005-02-18 2018-07-30 Abraxis Bioscience Llc Combinações e modos de administração de agentes terapêuticos e terapia de combinação
DE102005024157A1 (de) 2005-05-23 2006-11-30 Amedo Gmbh Nadelpositioniersystem
EA014350B1 (ru) 2005-05-24 2010-10-29 Мерк Сероно С.А. Производные тиазола и их применение
AU2006251159B2 (en) 2005-05-24 2011-09-22 Merck Serono Sa Thiazole derivatives and use thereof
DE102005024790A1 (de) 2005-05-26 2006-12-07 Eos Gmbh Electro Optical Systems Strahlungsheizung zum Heizen des Aufbaumaterials in einer Lasersintervorrichtung
US7655446B2 (en) 2005-06-28 2010-02-02 Vertex Pharmaceuticals Incorporated Crystal structure of Rho-kinase I kinase domain complexes and binding pockets thereof
DE102005048072A1 (de) 2005-09-24 2007-04-05 Bayer Cropscience Ag Thiazole als Fungizide
CN101331125A (zh) 2005-12-12 2008-12-24 健亚生物科技公司 N-(5-元杂芳香环)-酰胺基抗病毒化合物
GB0525671D0 (en) 2005-12-16 2006-01-25 Novartis Ag Organic compounds
AU2007206860A1 (en) * 2006-01-23 2007-07-26 Laboratoires Serono S.A. Thiazole derivatives and use thereof
US20070259855A1 (en) 2006-04-06 2007-11-08 Udo Maier Thiazolyl-dihydro-indazole
JP2009535386A (ja) * 2006-05-03 2009-10-01 アストラゼネカ アクチボラグ チアゾール誘導体および抗腫瘍剤としてのその使用
GB0610243D0 (en) 2006-05-23 2006-07-05 Novartis Ag Organic compounds
GB0612630D0 (en) * 2006-06-26 2006-08-02 Novartis Ag Organic compounds
FR2904190B1 (fr) 2006-07-25 2008-12-12 Inst Rech Pour Le Dev I R D Et Utilisation d'inocula fongiques pour l'amelioration de la production maraichere
TW200827368A (en) 2006-11-21 2008-07-01 Genelabs Tech Inc Amido anti-viral compounds
WO2008124000A2 (en) 2007-04-02 2008-10-16 Ligand Pharmaceuticals Incorporated Thiazole derivatives as androgen receptor modulator compounds
RU2479577C2 (ru) 2007-05-25 2013-04-20 Эбботт Гмбх Унд Ко.Кг Гетероциклические соединения в качестве положительных модуляторов метаботропного глутаматного рецептора 2 (рецептора mglu2)
WO2009003009A1 (en) 2007-06-26 2008-12-31 Enanta Pharmaceuticals, Inc. Substituted pyrrolidine as anti-infectives
AU2008275891B2 (en) 2007-07-19 2013-10-10 H.Lundbeck A/S 5-membered heterocyclic amides and related compounds
WO2009080694A1 (en) 2007-12-20 2009-07-02 Novartis Ag Thiazole derivatives used as pi 3 kinase inhibitors
ITMI20072396A1 (it) 2007-12-20 2009-06-21 Dachi S R L "apparato di chiusura di contenitori di materiale biologico"
JP2011506563A (ja) 2007-12-20 2011-03-03 ノバルティス アーゲー ビスチアゾール誘導体、その製造方法および医薬品としてのその使用
UA104147C2 (uk) * 2008-09-10 2014-01-10 Новартис Аг Похідна піролідиндикарбонової кислоти та її застосування у лікуванні проліферативних захворювань

Also Published As

Publication number Publication date
DK2331537T3 (en) 2016-01-25
HUE025884T2 (en) 2016-05-30
CY2020037I1 (el) 2021-03-12
AU2009290904A1 (en) 2010-03-18
BRPI0918750B8 (pt) 2021-05-25
EA018863B1 (ru) 2013-11-29
RS54476B1 (sr) 2016-06-30
IL210976A (en) 2014-09-30
LTPA2020534I1 (lt) 2020-12-28
BRPI0918750A2 (pt) 2020-08-04
US8476268B2 (en) 2013-07-02
BRPI0918750B1 (pt) 2020-12-22
TN2011000053A1 (en) 2012-09-05
SI2331537T1 (sl) 2016-02-29
TW201014851A (en) 2010-04-16
ME01284B (me) 2013-06-20
TWI453206B (zh) 2014-09-21
US20140186469A1 (en) 2014-07-03
GEP20135991B (en) 2013-12-25
CY1117078T1 (el) 2017-04-05
CU20110052A7 (es) 2011-12-28
MY151556A (en) 2014-06-13
LUC00186I2 (ar) 2024-07-01
PL2331537T3 (pl) 2016-06-30
CO6351738A2 (es) 2011-12-20
SV2011003853A (es) 2011-05-16
CU24000B1 (es) 2014-06-27
CN102149711A (zh) 2011-08-10
SMAP201100019A (it) 2011-05-06
IL210976A0 (en) 2011-04-28
AU2009290904B2 (en) 2012-08-30
HK1156305A1 (en) 2012-06-08
DOP2011000070A (es) 2011-03-31
KR20110038737A (ko) 2011-04-14
HN2011000699A (es) 2013-12-02
NZ590754A (en) 2012-08-31
AR112074A2 (es) 2019-09-18
ZA201100699B (en) 2012-08-29
JP5486601B2 (ja) 2014-05-07
PT2331537E (pt) 2016-03-03
ES2560673T3 (es) 2016-02-22
PA8841901A1 (es) 2010-06-28
NL301071I1 (nl) 2020-11-11
CR20110059A (es) 2011-03-28
MA32604B1 (ar) 2011-09-01
AR073369A1 (es) 2010-11-03
NO2020037I1 (no) 2020-11-16
EA201100447A1 (ru) 2011-10-31
CA2734819A1 (en) 2010-03-18
US8227462B2 (en) 2012-07-24
MX2011002597A (es) 2011-07-21
US20140005232A1 (en) 2014-01-02
FIC20200046I1 (fi) 2020-11-26
EP2331537A1 (en) 2011-06-15
HUS2000044I1 (hu) 2020-12-28
WO2010029082A1 (en) 2010-03-18
CN102149711B (zh) 2014-09-10
SMP201100019B (it) 2012-01-18
HRP20160014T1 (hr) 2016-02-12
JP2012502080A (ja) 2012-01-26
PE20110796A1 (es) 2011-11-04
NI201100049A (es) 2011-07-26
US20100105711A1 (en) 2010-04-29
UY32096A (es) 2010-04-30
NL301071I2 (nl) 2020-12-01
CY2020037I2 (el) 2021-03-12
EP2331537B1 (en) 2015-10-28
LTC2331537I2 (lt) 2022-01-10
KR101290844B1 (ko) 2013-07-29
CL2011000504A1 (es) 2011-07-15
UA104147C2 (uk) 2014-01-10
ECSP11010880A (es) 2011-04-29
US8710085B2 (en) 2014-04-29
US20120263712A1 (en) 2012-10-18
CA2734819C (en) 2017-10-24

Similar Documents

Publication Publication Date Title
JO3121B1 (ar) مشتقات 1 - ((5-هيتيرورلثيازول-2-يل) أمينوكاربونيل) بيروليدين-2-كربوكساميد كمثبات الفوسفاتديلينوسيتول 3-كيناس (pi3k) مفيدة في علاج الأمراض التصاعدية
TN2010000293A1 (en) Thiazole derivatives used as pi 3 kinase inhibitors
EA201101341A1 (ru) Соединения, ингибирующие киназы, и фармацевтическая композиция на их основе
GEP20135785B (en) Pyrrolopyrimidine compounds as cdk inhibitors
EA200970156A1 (ru) Пиридизиноновые производные
EA201071339A1 (ru) Фосфорсодержащие производные в качестве ингибиторов киназы
EA200801996A1 (ru) 2-замещенные производные 4-бензилфталазинонов в качестве гистаминовых h1- и h3-антагонистов
MX2013001361A (es) 4-(1h-indol-3-il) - pirimidina como inhibidores de alk.
EA201001683A1 (ru) Производные фенил- или пиридинилзамещенных индазолов
UA94129C2 (ru) Соединения для ингибирования митоза
EA201100580A1 (ru) Имидазопиридазинкарбонитрилы, используемые в качестве ингибиторов киназы
MX2012000711A (es) Inhibidores de pirrolopirazina de cinasas.
MX2012013197A (es) Inhibidores de indazol de cinasa.
EA201291356A1 (ru) Пиперидиноновые производные как ингибиторы mdm2 для лечения рака
EA201590748A1 (ru) Противовирусные соединения против rsv
MX2009003834A (es) Derivados de pirrolidina como inhibidores de iap.
EA201290183A1 (ru) Бензодиазепиновый ингибитор бромодомена
MY160454A (en) Oxazole substituted indazoles as pi3-kinase inhibitors
MX2015017192A (es) Inhibidores de fosfatidilinositol 3-cinasa.
EA201291217A1 (ru) ФАРМАЦЕВТИЧЕСКИЕ КОМПОЗИЦИИ, СОДЕРЖАЩИЕ ПРОИЗВОДНЫЕ 1-(β-D-ГЛЮКОПИРАНОЗИЛ)-2-ТИЕНИЛМЕТИЛБЕНЗОЛА КАК ИНГИБИТОРЫ НЗПГ
MY149512A (en) Pyrazolylaminopyridine derivatives useful as kinase inhibitors
MX2012000177A (es) 2-carboxamida-cicloamino-ureas sustituidas.
PH12013500644A1 (en) Co-crystals and salts of ccr3-inhibitors
ATE517873T1 (de) 6-oxo-1,6-dihydropyrimidin-2-yle bei der behandlung proliferativer krankheiten
MX2008016358A (es) Derivados de tiazolil-urea como inhibidores de cinasa de fosfatidil-inositol-3.